Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pengcheng Shi

Showing results (161-170 of 182) with videos related to

Pageof 19
Sort By:
The Lancet Regional Health. Western Pacific|August 20, 2025
Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trialQifa Liu, Zhongli Hu, Na Xu, et al.
The Lancet. Haematology|January 26, 2023
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trialLi Xuan, Min Dai, Erlie Jiang, et al.
Blood Advances|January 3, 2024
A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AMLZhibo Zhang, Jia Yin, Guoli Lian, et al.
The Lancet. Oncology|August 14, 2020
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trialLi Xuan, Yu Wang, Fen Huang, et al.
BMJ Open|December 30, 2023
Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort studyLinjing Cai, Huan Chen, Yongqiang Wei, et al.
Oncotarget|January 2, 2018
Defined, serum/feeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemiaZhiwu Jiang, Di Wu, Wei Ye, et al.
Experimental Hematology & Oncology|February 4, 2026
Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AMLGuo Qiu, Zhao Yin, Xiaoyue Lu, et al.
Journal of Hematology & Oncology|April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialHua Jin, Yu Zhang, Sijian Yu, et al.
Blood Cancer Journal|December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomesSijian Yu, Tong Lin, Danian Nie, et al.
The Lancet. Haematology|July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trialLi Xuan, Yu Wang, Kaibo Yang, et al.
Pageof 19

Showing results (161-170 of 182) with videos related to

Sort By:
Pageof 19
The Lancet Regional Health. Western Pacific|August 20, 2025
Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trialQifa Liu, Zhongli Hu, Na Xu, et al.
The Lancet. Haematology|January 26, 2023
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trialLi Xuan, Min Dai, Erlie Jiang, et al.
Blood Advances|January 3, 2024
A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AMLZhibo Zhang, Jia Yin, Guoli Lian, et al.
The Lancet. Oncology|August 14, 2020
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trialLi Xuan, Yu Wang, Fen Huang, et al.
BMJ Open|December 30, 2023
Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort studyLinjing Cai, Huan Chen, Yongqiang Wei, et al.
Oncotarget|January 2, 2018
Defined, serum/feeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemiaZhiwu Jiang, Di Wu, Wei Ye, et al.
Experimental Hematology & Oncology|February 4, 2026
Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AMLGuo Qiu, Zhao Yin, Xiaoyue Lu, et al.
Journal of Hematology & Oncology|April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialHua Jin, Yu Zhang, Sijian Yu, et al.
Blood Cancer Journal|December 7, 2021
Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomesSijian Yu, Tong Lin, Danian Nie, et al.
The Lancet. Haematology|July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trialLi Xuan, Yu Wang, Kaibo Yang, et al.
Pageof 19